Fig. 7: A schematic model of c-myc/miR-29b-3p/CDK6 axis in the regulation of palbociclib sensitivity in breast cancer cells.
From: c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis
Mycro3, a selective c-myc inhibitor, inhibit the expression of c-myc. c-myc could negatively regulate miR-29b-3p expression by binding to the promoter region of miR-29b-3p. miR-29b-3p negatively modulate CDK6 expression by directly targeting its 3'-UTR, leding to the enhanced palbociclib sensitivity and induced tumor growth.
